ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Advanced Search

Protocol Cidofovir for Refractory Polyomavirus Associated Nephropathy in Kidney Transplant Recipients

J. Clark, A. Haririan

University of Maryland Medical Center, Baltimore, MD

Meeting: 2019 American Transplant Congress

Abstract number: C265

Keywords: Graft function, Kidney transplantation, Polyma virus, Viral therapy

Session Information

Date: Monday, June 3, 2019

Session Name: Poster Session C: Kidney: Polyoma

Session Time: 6:00pm-7:00pm

 Presentation Time: 6:00pm-7:00pm

Location: Hall C & D

Related Abstracts
  • Cidofovir for BK Nephropathy Rescue Treatment: A Single Center Experience
  • Outcomes of Transplant Recipients Treated with Cidofovir for Resistant or Refractory Cytomegalovirus Infection.

*Purpose: Dose-limiting nephrotoxicity has historically precluded the use of cidofovir for polyomavirus associated nephropathy (PVAN). With incidence of BK viremia in kidney transplant recipients increasing at our center over the past year, we sought to describe the impact of protocolized cidofovir for refractory PVAN.

*Methods: Renal transplant recipients between 2010-2017 with biopsy-proven PVAN and BK viremia who received cidofovir were included.

*Results: In the study period, 10 cases of cidofovir treatment for PVAN were identified. Select characteristics and treatment details are outlined in [Table 1]. 90% of patients received lymphocyte-depleting induction therapy. All patients underwent reduction of maintenance immunosuppression and 60% of patients received IVIG prior to cidofovir initiation. Cidofovir was administered at a median of 228 (104-2714) days post-transplant, with pre and post-administration fluids, and without probenecid. At initiation of cidofovir treatment, subjects had mean SV40 staining of 40% (10-80) on biopsy, BK viremia of 217,421 copies/mL (7400-740,000), and creatinine of 2mg/dL (0.9-8.7). At completion of cidofovir treatment, mean SV40 staining decreased to 15% (0-15), median BK viremia decreased to 5600 copies/mL (<1500-31,000) and creatinine decreased to 1.8mg/dL (0.9-7). [Table 2]. While two patients suffered graft loss, one was attributed to both mixed rejection and PVAN.

*Conclusions: After decreasing maintenance immunosuppression, and after IVIG treatment, cidofovir is reasonable to consider for refractory PVAN in kidney transplant recipients.

 border=

 border=

  • Tweet
  • Email
  • Print

To cite this abstract in AMA style:

Clark J, Haririan A. Protocol Cidofovir for Refractory Polyomavirus Associated Nephropathy in Kidney Transplant Recipients [abstract]. Am J Transplant. 2019; 19 (suppl 3). https://atcmeetingabstracts.com/abstract/protocol-cidofovir-for-refractory-polyomavirus-associated-nephropathy-in-kidney-transplant-recipients/. Accessed February 27, 2021.

« Back to 2019 American Transplant Congress

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • A Decade of Donor-Derived Disease: A Report of the OPTN Ad Hoc Disease Transmission Advisory Committee (DTAC).
  • Low GFR after Kidney Donation Is Not Chronic Kidney Disease
  • Subtherapeutic Low Tacrolimus Trough Levels (≤3.5 Ng /ml) Are A Risk Factor For Acute Rejection And Creatinine Doubling.
  • Is There a Difference Between DCD and DBD Kidney Transplantation with Similar KDPI?
  • Kidney Dialysis after Heart Transplantation: The Short and Long Term Outcomes
  • Low GFR after Kidney Donation Is Not Chronic Kidney Disease
  • Subtherapeutic Low Tacrolimus Trough Levels (≤3.5 Ng /ml) Are A Risk Factor For Acute Rejection And Creatinine Doubling.
  • Penis Transplantation: First U.S. Experience.
  • A Decade of Donor-Derived Disease: A Report of the OPTN Ad Hoc Disease Transmission Advisory Committee (DTAC).
  • Is There a Difference Between DCD and DBD Kidney Transplantation with Similar KDPI?
  • Penis Transplantation: First U.S. Experience.
  • Is There a Difference Between DCD and DBD Kidney Transplantation with Similar KDPI?
  • Low GFR after Kidney Donation Is Not Chronic Kidney Disease
  • Evidence of a Clinically Significant Drug-Drug Interaction between Cannabidiol and Tacrolimus: A Case Report
  • Kidney Dialysis after Heart Transplantation: The Short and Long Term Outcomes

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2021 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.